Core Insights - Baxter International Inc. is a global healthcare company providing essential medical products, operating in a competitive landscape with peers like Medtronic and Becton Dickinson [1] - Morgan Stanley set a new price target for Baxter at $15, indicating a potential downside of approximately -21.38% from the current trading price of $19.08 [1][5] - Faruqi & Faruqi, LLP is investigating potential claims against Baxter for investors who purchased securities between February 23, 2022, and July 30, 2025 [2][4][5] Company Performance - Baxter's current stock price is $19.08, reflecting an increase of 1.81% or $0.34, with a trading volume of 8,389,032 shares [3][5] - The stock has fluctuated between a low of $18.55 and a high of $19.20 on the current trading day [3] - Over the past year, Baxter's stock reached a high of $37.74 and a low of $17.40 [3] - The company has a market capitalization of approximately $9.81 billion [3][5]

Group 1 - A shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired the securities of DeFi Technologies Inc. between May 12, 2025, and November 14, 2025 [1] - The lawsuit alleges that Defendants made misrepresentations regarding the Company's revenue guidance for fiscal year 2025 [2] - Investors wishing to serve as lead plaintiff must file papers by January 30, 2026, and representation is on a contingency fee basis, meaning shareholders pay no fees or expenses [3] Group 2 - Bernstein Liebhard LLP has recovered over $3.5 billion for its clients since 1993 and has represented both individual investors and large public and private pension funds [4]

Core Points - A class action securities lawsuit has been filed against DexCom, Inc. for alleged securities fraud affecting investors between January 8, 2024, and September 17, 2025 [1] Group 1: Allegations - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval [2] - These design changes allegedly made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [2] - The enhancements to the G7's reliability, accuracy, and functionality were reportedly overstated by the defendants [2] - The true scope and severity of the issues with the G7 devices were downplayed, increasing the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [2] - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [2] Group 2: Legal Process - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - Rosen Law Firm is urging investors of Cepton, Inc. to secure legal counsel before the December 8, 2025 deadline for a securities class action related to misleading statements made by the company during the class period from July 29, 2024, to January 6, 2025 [1][5]. Group 1: Legal Action Details - Investors who purchased or sold Cepton common stock during the specified class period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 8, 2025 deadline to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3][6]. - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations, including failing to disclose a credible third-party bid that valued Cepton at more than double the Koito Acquisition [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against WPP plc due to allegations of false and misleading statements regarding the company's expected revenue for fiscal year 2025, which led to significant losses for investors [4][6]. Group 1: Allegations and Legal Actions - The complaint alleges that WPP and its executives violated federal securities laws by making false statements and failing to disclose material information about the company's media division and its ability to handle macroeconomic challenges [6]. - WPP's executives expressed confidence in revitalizing the media division and claimed that new business wins would offset losses, while concealing the true state of the media arm [6]. - A federal securities class action has been filed against WPP, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [4][9]. Group 2: Impact on Stock Price - Following WPP's trading update on July 9, 2025, which indicated a deterioration in performance, the company's stock price fell from $35.82 to $29.34, representing an 18.1% decline in one day [7][8]. - The trading update attributed the decline to macroeconomic uncertainties and weaker new business, compounded by ongoing restructuring efforts within WPP Media [7]. Group 3: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses to contact the firm to discuss their legal rights and options [1][10]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [5].

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages StubHub Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - STUBNovember 28, 2025 3:01 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 28, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of StubHub Holdings, Inc. (NYSE: STUB) pursuant and/or traceable to the Registration State ...

Core Viewpoint - Rosen Law Firm is encouraging investors of Cepton, Inc. to secure legal counsel before the December 8, 2025 deadline for a securities class action related to the company's stock transactions during the specified class period [1][2]. Group 1: Class Action Details - The class period for the Cepton, Inc. securities class action is from July 29, 2024, to January 6, 2025 [1]. - Investors who purchased or sold Cepton common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Allegations Against Cepton - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations, particularly concerning a third-party bid that valued Cepton at more than double the Koito Acquisition [5]. - It is claimed that the Board of Directors failed to adequately explore this offer and did not disclose its terms, depriving shareholders of the opportunity to make an informed decision regarding the Koito Acquisition [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. regarding alleged violations of federal securities laws related to misleading statements about the efficacy of its drug, efzofitimod, leading to significant financial losses for investors [3][6]. Group 1: Legal Action and Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in aTyr Pharma to contact them for discussing legal options, particularly for those who purchased securities between January 16, 2025, and September 12, 2025 [2][3]. - A federal securities class action has been filed against aTyr Pharma, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [3][8]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Allegations Against aTyr Pharma - The complaint alleges that aTyr Pharma and its executives made false and misleading statements regarding the drug efzofitimod, particularly about its ability to allow patients to taper off steroid usage completely [6]. - The EFZO-FIT study results indicated that efzofitimod did not show a significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [7]. - Following the release of the study results, aTyr's stock price plummeted by 83.25%, dropping from $6.03 on September 12 to $1.01 on September 15 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against StubHub Holdings, Inc. due to allegations of misleading information in the company's registration statement during its IPO on September 17, 2025 [2][4]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in StubHub to contact them for discussing legal options [1]. - The firm is reminding investors of the January 23, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against StubHub [2]. Allegations Against StubHub - The class action complaint alleges that the registration statement was materially false and/or misleading, failing to disclose significant adverse facts about the company's business and operations [4]. - Specific undisclosed issues included changes in payment timing to vendors, which adversely affected free cash flow, leading to misleading reports [4]. Financial Performance - StubHub's IPO priced at $23.50 per share, with approximately 34 million shares sold [4]. - Following the release of third-quarter financial results on November 13, 2025, the company reported a free cash flow of negative $4.6 million, a 143% decrease from the previous year's positive $10.6 million [5]. - The company's net cash provided by operating activities was reported at $3.8 million, a 69.3% decrease from $12.4 million in the prior year [5][6]. Stock Price Impact - After the negative financial news, StubHub's stock price fell by $3.95 per share, or 20.9%, closing at $14.87 on November 14, 2025 [7]. - By the time of the legal action, the stock was trading as low as $10.31 per share, representing a nearly 56% decline from the IPO price [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Stride, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The Class Period for the Stride securities is from October 22, 2024, to October 28, 2025, and the lead plaintiff deadline is January 12, 2026 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [3] Group 3: Allegations Against Stride, Inc. - The lawsuit alleges that Stride made misleading statements regarding its products and services, inflating enrollment numbers and cutting staff costs beyond statutory limits [4] - The firm claims that these actions led to damages for investors when the true situation was revealed [4]